A Phase 3 interventional study of pegylated interferon alpha-2b and pegylated interferon alpha-2b in Hepatitis B, Chronic, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-04-07.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing peginterferon alfa-2b in Hepatitis B, Chronic — 5 open to participants now, 5 under way, none of them phase 3. peginterferon alfa-2b · Hepatitis B, Chronic.
Among the 15 studies testing peginterferon alfa-2b in Hepatitis B, Chronic, this one is the 2nd largest by enrollment, is the only one that started in 2007, is one of 5 in phase 3, and was the 1st registered.
896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.
Browse Hepatitis B, Chronic studies →5 of the 15 studies testing peginterferon alfa-2b in Hepatitis B, Chronic are open now, in 1 country. Recruiting first, the newest first:
Third Affiliated Hospital, Sun Yat-Sen University · Sites in China
Ages 18–60
Beijing Ditan Hospital · Sites in China
Ages 18–65 · Women only
Ningbo No.2 Hospital · Sites in China
Ages 18–65
Nanfang Hospital, Southern Medical University · Sites in China
Ages 3–18
Huashan Hospital · Sites in China
Ages 18–65
By country, each count listing its studies:
peginterferon alfa-2b: first FDA approval 2001 (PEGINTRON), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 1 · Phase 3 5 · Phase 4 5
First in 2005; this study’s year is marked. 1 started in 2007.
This study's enrollment of 671 is above the median of 100 across 659 interventional studies indexed under Hepatitis B, Chronic.
Median enrollment 254 across the 15 interventional studies. Of the 6 that completed or were terminated, 3 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 15 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Merck & Co., Inc has 3 studies filed under Hepatitis B, Chronic — fewer than ten, so there is no comparison to draw.
1 of the studies testing peginterferon alfa-2b in Hepatitis B, Chronic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05182463Third Affiliated Hospital, Sun Yat-Sen UniversityPeginterferon Treatment Study for Inactive Chronic Hepatitis B Patients | 2026-12-13 |
Add it to your calendar (.ics) → With an account.
Among the 15 studies testing peginterferon alfa-2b in Hepatitis B, Chronic, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the efficacy and safety of two dosages of PegIntron for treating hepatitis B e antigen (HBeAg) positive chronic hepatitis B compared with the approved dosage, which is PegIntron 1.0 microgram (mcg)/kg given once a week for 24 weeks. This study compares dosages of (1) 1.5 mcg/kg once a week for 24 weeks and (2) 1.5 mcg/kg once a week for 48 weeks with the approved dosage. All subjects are followed for 24 weeks after their treatment ends.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Adults with chronic :
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PegIntron 1.0 mcg/kg weekly (QW) \* 24 weeks + 24 weeks follow-up
Drug: pegylated interferon alpha-2b
PegIntron 1.5 mcg/kg QW \* 24 wks + 24 wks follow-up
Drug: pegylated interferon alpha-2b
PegIntron 1.5 mcg/kg QW \* 48 wks + 24 wks follow-up
Drug: pegylated interferon alpha-2b
1.0 mcg/kg subcutaneously (S.C.) QW for 24 weeks
1.5 mcg/kg S.C. QW for 24 weeks
1.5 mcg/kg S.C. QW for 48 weeks
Number of Participants With Hepatitis B Envelope Antigen (HBe or HBeAg) Loss
HBeAg Loss was tested by Abbott Microparticle Enzyme Immunoassay (MEIA)
Time frame: 24 weeks after end of treatment (EOT)
Number of Participants With HBeAg Loss
HBeAg Loss was tested by assay of Abbott MEIA
Time frame: Up to Treatment Week 48
HBe Seroconversion
HBe seroconversion was defined as HBeAg Loss and Anti-HBeAg Positive. These were tested by assay of Abbott MEIA.
Time frame: End of treatment (EOT) and 24 weeks after EOT
Number of Participants With Hepatitis B Virus - Deoxyriboncleic Acid (HBV-DNA) <20,000 IU/mL
HBV-DNA was tested by assay of Roche Cobas Taqman (the test lowest limit is 6 IU/mL)
Time frame: End of treatment (EOT) and 24 weeks after EOT
Number of Participants With HBV-DNA < 200 IU/mL
HBV-DNA was tested by assay of Roche Cobas Taqman (the test lowest limit is 6 IU/mL)
Time frame: End of treatment (EOT) and 24 weeks after EOT
Number of Participants With HBV-DNA Undetectable
Undetectable HBV-DNA was defined as having a level \<6 IU/mL by polymerase chain reaction (PCR).
Time frame: End of treatment (EOT) and 24 weeks after EOT
Number of Participants With Biochemical Response
Biochemical response was defined as alanine aminotransferase (ALT) normalization.
Time frame: End of treatment (EOT) and 24 weeks after EOT
Number of Participants With Combined Response
Combined response was defined as HBV DNA \<20,000 IU/mL and HBe seroconversion and alanine aminotransferase (ALT) normalization
Time frame: End of treatment (EOT) and 24 weeks after EOT
Hepatitis B Surface Antigen (HBsAg) Loss
HBsAg Loss was tested by assay of Abbott MEIA
Time frame: End of treatment (EOT) and 24 weeks after EOT
Hepatitis B Surface Antigen (HBs) Seroconversion
HBs seroconversion was defined as having HBsAg Loss and Anti-HBs Positive
Time frame: End of treatment (EOT) and 24 weeks after EOT
Change From Baseline in Liver Biopsy Score
Method for biopsy scoring was Knodell Scoring System (Histology Activity Index-HAI Score System): Score I (periportal +/- bridging necrosis): 0 (none) to 10 (multilobular necrosis). Score II (Intralobular degeneration and focal necrosis): 0 (none) to 4 (Marked \[involvement of \>2/3 of lobules or nodules\]). Score III (portal inflammation): 0 (none) to 4 (Marked \[dense packing of inflammatory cells in \>2/3 of portal tracts\]). Score IV (fibrosis): 0 (none) to 4 (cirrhosis).
Time frame: Baseline to 24 weeks after end of treatment
| Milestone | PEG 1.0 mcg/kg Weekly (QW) * 24 Weeks | PEG 1.5 mcg/kg QW * 24 Weeks | PEG 1.5 mcg/kg QW * 48 Weeks |
|---|---|---|---|
| Started | 225 | 221 | 225 |
| Completed | 214 | 207 | 204 |
| Not completed | 11 | 14 | 21 |
| Withdrew: Adverse event | 5 | 5 | 7 |
| Withdrew: Lost to follow-up | 3 | 4 | 4 |
| Withdrew: Subject withdrew - not treatment related | 2 | 0 | 5 |
| Withdrew: Subject withdrew - treatment related | 0 | 3 | 2 |
| Withdrew: Noncompliance with protocol | 0 | 0 | 1 |
| Withdrew: Did not meet protocol eligibility | 1 | 2 | 2 |
HBeAg Loss was tested by Abbott Microparticle Enzyme Immunoassay (MEIA)
| Participants | PEG 1.0 mcg/kg Weekly (QW) * 24 Weeks | PEG 1.5 mcg/kg QW * 24 Weeks | PEG 1.5 mcg/kg QW * 48 Weeks |
|---|---|---|---|
| Number of Participants With Hepatitis B Envelope Antigen (HBe or HBeAg) Loss | 39 | 40 | 70 |
HBeAg Loss was tested by assay of Abbott MEIA
| Participants | PEG 1.0 mcg/kg Weekly (QW) * 24 Weeks | PEG 1.5 mcg/kg QW * 24 Weeks | PEG 1.5 mcg/kg QW * 48 Weeks |
|---|---|---|---|
| Number of Participants With HBeAg Loss | 31 | 28 | 43 |
HBe seroconversion was defined as HBeAg Loss and Anti-HBeAg Positive. These were tested by assay of Abbott MEIA.
| Participants | PEG 1.0 mcg/kg Weekly (QW) * 24 Weeks | PEG 1.5 mcg/kg QW * 24 Weeks | PEG 1.5 mcg/kg QW * 48 Weeks |
|---|---|---|---|
| EOT | 31 | 27 | 40 |
| 24 weeks after EOT | 38 | 36 | 67 |
HBV-DNA was tested by assay of Roche Cobas Taqman (the test lowest limit is 6 IU/mL)
| Participants | PEG 1.0 mcg/kg Weekly (QW) * 24 Weeks | PEG 1.5 mcg/kg QW * 24 Weeks | PEG 1.5 mcg/kg QW * 48 Weeks |
|---|---|---|---|
| EOT | 46 | 61 | 76 |
| 24 weeks after EOT | 44 | 47 | 75 |
HBV-DNA was tested by assay of Roche Cobas Taqman (the test lowest limit is 6 IU/mL)
| Participants | PEG 1.0 mcg/kg Weekly (QW) * 24 Weeks | PEG 1.5 mcg/kg QW * 24 Weeks | PEG 1.5 mcg/kg QW * 48 Weeks |
|---|---|---|---|
| EOT | 10 | 14 | 21 |
| 24 weeks after EOT | 12 | 12 | 22 |
Undetectable HBV-DNA was defined as having a level \<6 IU/mL by polymerase chain reaction (PCR).
| Participants | PEG 1.0 mcg/kg Weekly (QW) * 24 Weeks | PEG 1.5 mcg/kg QW * 24 Weeks | PEG 1.5 mcg/kg QW * 48 Weeks |
|---|---|---|---|
| EOT | 4 | 3 | 8 |
| 24 weeks after EOT | 4 | 3 | 8 |
Biochemical response was defined as alanine aminotransferase (ALT) normalization.
| Participants | PEG 1.0 mcg/kg Weekly (QW) * 24 Weeks | PEG 1.5 mcg/kg QW * 24 Weeks | PEG 1.5 mcg/kg QW * 48 Weeks |
|---|---|---|---|
| EOT | 75 | 86 | 103 |
| 24 weeks after EOT | 63 | 80 | 103 |
Combined response was defined as HBV DNA \<20,000 IU/mL and HBe seroconversion and alanine aminotransferase (ALT) normalization
| Participants | PEG 1.0 mcg/kg Weekly (QW) * 24 Weeks | PEG 1.5 mcg/kg QW * 24 Weeks | PEG 1.5 mcg/kg QW * 48 Weeks |
|---|---|---|---|
| EOT | 11 | 11 | 23 |
| 24 weeks after EOT | 18 | 23 | 45 |
HBsAg Loss was tested by assay of Abbott MEIA
| Participants | PEG 1.0 mcg/kg Weekly (QW) * 24 Weeks | PEG 1.5 mcg/kg QW * 24 Weeks | PEG 1.5 mcg/kg QW * 48 Weeks |
|---|---|---|---|
| EOT | 1 | 1 | 4 |
| 24 weeks after EOT | 1 | 1 | 4 |
HBs seroconversion was defined as having HBsAg Loss and Anti-HBs Positive
| Participants | PEG 1.0 mcg/kg Weekly (QW) * 24 Weeks | PEG 1.5 mcg/kg QW * 24 Weeks | PEG 1.5 mcg/kg QW * 48 Weeks |
|---|---|---|---|
| EOT | 0 | 0 | 1 |
| 24 weeks after EOT | 0 | 0 | 2 |
Method for biopsy scoring was Knodell Scoring System (Histology Activity Index-HAI Score System): Score I (periportal +/- bridging necrosis): 0 (none) to 10 (multilobular necrosis). Score II (Intralobular degeneration and focal necrosis): 0 (none) to 4 (Marked \[involvement of \>2/3 of lobules or nodules\]). Score III (portal inflammation): 0 (none) to 4 (Marked \[dense packing of inflammatory cells in \>2/3 of portal tracts\]). Score IV (fibrosis): 0 (none) to 4 (cirrhosis).
| Units on a scale | PEG 1.0 mcg/kg Weekly (QW) * 24 Weeks | PEG 1.5 mcg/kg QW * 24 Weeks | PEG 1.5 mcg/kg QW * 48 Weeks |
|---|---|---|---|
| Baseline | 8.0 ± 3.06 | 8.4 ± 2.92 | 8.2 ± 3.33 |
| Change from Baseline | -1.1 ± 3.57 | -1.7 ± 3.66 | -1.6 ± 3.96 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PEG 1.0 mcg/kg QW x24 Weeks | — | 10/225 (4.4%) | 173/225 (76.9%) |
| PEG 1.5 mcg/kg QW x24 Weeks | — | 11/221 (5%) | 169/221 (76.5%) |
| PEG 1.5 mcg/kg QW x48 Weeks | — | 15/224 (6.7%) | 182/224 (81.3%) |
| Event | PEG 1.0 mcg/kg QW x24 Weeks | PEG 1.5 mcg/kg QW x24 Weeks | PEG 1.5 mcg/kg QW x48 Weeks |
|---|---|---|---|
| ALANINE AMINOTRANSFERASE INCREASEDInvestigations | 1/225 | 4/221 | 2/224 |
| ASPARTATE AMINOTRANSFERASE INCREASEDInvestigations | 0/225 | 4/221 | 0/224 |
| HEPATITISHepatobiliary disorders | 4/225 | 0/221 | 1/224 |
| FATIGUEGeneral disorders | 1/225 | 3/221 | 0/224 |
| DECREASED APPETITEMetabolism and nutrition disorders | 1/225 | 3/221 | 0/224 |
| HEPATITIS BInfections and infestations | 1/225 | 2/221 | 3/224 |
| DEPRESSIONPsychiatric disorders | 0/225 | 2/221 | 0/224 |
| GASTROOESOPHAGEAL REFLUX DISEASEGastrointestinal disorders | 0/225 | 1/221 | 0/224 |
| NAUSEAGastrointestinal disorders | 0/225 | 1/221 | 1/224 |
| HEPATIC FUNCTION ABNORMALHepatobiliary disorders | 1/225 | 1/221 | 0/224 |
| Event | PEG 1.0 mcg/kg QW x24 Weeks | PEG 1.5 mcg/kg QW x24 Weeks | PEG 1.5 mcg/kg QW x48 Weeks |
|---|---|---|---|
| PYREXIAGeneral disorders | 156/225 | 158/221 | 168/224 |
| MYALGIAMusculoskeletal and connective tissue disorders | 54/225 | 70/221 | 77/224 |
| HEADACHENervous system disorders | 47/225 | 66/221 | 59/224 |
| FATIGUEGeneral disorders | 35/225 | 29/221 | 42/224 |
| ALOPECIASkin and subcutaneous tissue disorders | 15/225 | 19/221 | 28/224 |
| ASTHENIAGeneral disorders | 12/225 | 25/221 | 15/224 |
| DIZZINESSNervous system disorders | 18/225 | 21/221 | 22/224 |
| ARTHRALGIAMusculoskeletal and connective tissue disorders | 18/225 | 14/221 | 12/224 |
| DECREASED APPETITEMetabolism and nutrition disorders | 8/225 | 16/221 | 17/224 |
| WEIGHT DECREASEDInvestigations | 5/225 | 3/221 | 16/224 |
| Age, Continuous(Years) | PEG 1.0 mcg/kg QW * 24 Weeks | PEG 1.5 mcg/kg QW * 24 Weeks | PEG 1.5 mcg/kg QW * 48 Weeks | Total |
|---|---|---|---|---|
| Mean | 28.2 ± 7.2 | 27.5 ± 7.1 | 28.4 ± 7.6 | 28.0 ± 7.3 |
| Sex: Female, Male(Participants) | PEG 1.0 mcg/kg QW * 24 Weeks | PEG 1.5 mcg/kg QW * 24 Weeks | PEG 1.5 mcg/kg QW * 48 Weeks | Total |
|---|---|---|---|---|
| Female | 54 | 57 | 55 | 166 |
| Male | 171 | 164 | 169 | 504 |
No study locations are listed for this record.
Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php
The record gives a start of Sep 2007, a primary completion of Nov 2009 and a completion of Nov 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2010, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Peginterferon alfa-2b